Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioHarvest SciencesBHST +0.70%63 Equity-to-Asset is 0.51 as of Mar. 2026, which is 1600% above its 10-year median of 0.03. GuruFocus rates BHST with a GF Score™ of 63/100 and a GF Value™ of $8.25 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,994 Consumer Packaged Goods companies, BioHarvest Sciences ranks worse than 54.61% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BioHarvest Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $23.02 Mil. BioHarvest Sciences's Total Assets for the quarter that ended in Mar. 2026 was $45.56 Mil.
Therefore, BioHarvest Sciences's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.51.
The historical rank and industry rank for BioHarvest Sciences's Equity-to-Asset or its related term are showing as below:
BHST'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.28 Med: 0.03 Max: 0.99
Current: 0.51
During the past 12 years, the highest Equity to Asset Ratio of BioHarvest Sciences was 0.99. The lowest was -1.28. And the median was 0.03.
BHST's Equity-to-Asset is ranked worse than 54.61% of 1994
companies
in the Consumer Packaged Goods industry
Industry Median: 0.55
vs BHST: 0.51
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioHarvest Sciences Equity-to-Asset Related Terms
BioHarvest Sciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BioHarvest Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BHST vs BFNH, LSF, HAIN: Equity-to-Asset Comparison
For the Packaged Foods subindustry, BioHarvest Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioHarvest Sciences Equity-to-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioHarvest Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioHarvest Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioHarvest Sciences (BHST) has a Equity-to-Asset of 0.51 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioHarvest Sciences and its competitors. This is 1600% above median its historical median of 0.03. According to the industry distribution chart, BioHarvest Sciences ranks #1089 out of 1994 companies in the Consumer Packaged Goods industry, placing it in the top 54.6%.
Is BioHarvest Sciences' Equity-to-Asset too high?
BioHarvest Sciences' current Equity-to-Asset of 0.51 is 1600% above median its 10-year median of 0.03. The Consumer Packaged Goods industry median Equity-to-Asset is 0.55. BioHarvest Sciences' value of 0.51 is 7.3% below this industry median. Based on the distribution chart, BioHarvest Sciences ranks #1089 out of 1994 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, BioHarvest Sciences has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' Equity-to-Asset compare to BFNH and LSF?
According to the Consumer Packaged Goods industry distribution chart, BioHarvest Sciences ranks #1089 out of 1994 companies for Equity-to-Asset. This places BioHarvest Sciences in the lower half of its industry. The industry median Equity-to-Asset is 0.55. BioHarvest Sciences' value of 0.51 is 7.3% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.55, BioHarvest Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.55, based on 1,994 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioHarvest Sciences's current Equity-to-Asset of 0.51 is 7.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioHarvest Sciences and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioHarvest Sciences's current Equity-to-Asset is 0.51, which is 1600% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.25, compared to a current price of $2.13 — trading 74.2% below its estimated fair value. The current Equity-to-Asset is 0.51, which is 1600% above median its 10-year median of 0.03 and 7.3% below the Consumer Packaged Goods industry median of 0.55. BioHarvest Sciences' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current Equity-to-Asset is 0.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioHarvest Sciences (BHST) Overvalued in 2026?
Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued.
The current stock price of $2.13 is trading 74.2% below its estimated GF Value™ of $8.25.
GuruFocus considers BioHarvest Sciences to be Possible Value Trap.
Key valuation signals for BHST:
Equity-to-Asset: 0.51 (1600% above median its 10-year median of 0.03)
GF Value™: $8.25 vs. price of $2.13 (74.2% below fair value)
Industry Position: 7.3% below the Consumer Packaged Goods median (#1089 of 1994)
No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
63GF Score
Get the complete analysis for BHST
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHST has been successfully added to your 
